FAST and Agile–the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin
PLOS ONE · 23.05.2024 · 19 (5) · e0303971
DOI: 10.1371/journal.pone.0303971 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift PLOS ONE, online erschienen am 23.05.2024. Verfasst von Madalina-Gabriela Taru und 13 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Cluj, Romania. Hauptthemen laut MEDLINE: Elasticity Imaging Techniques, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UEFISCDI, the Romanian Executive Agency for Higher Education, Research, Development, and Innovation Funding, Ministry of Scientific and Technological Development, Higher Education and Information Society, University of Medicine and Pharmacy “Iuliu Hațieganu” Cluj-Napoca.
Abstract (Originalsprache)
Background
MASLD is a prevalent chronic liver condition with substantial clinical implications. This study aimed to assess the effectiveness of three new, elastography-based, scoring systems for advanced fibrosis ≥F3 (Agile 3+), cirrhosis F4 (Agile 4), and fibrotic NASH: NASH + NAS ≥4 + F≥2 (FAST score), in a cohort of biopsy-proven NAFLD meeting MASLD criteria. Our secondary aim was to compare their diagnostic performances with those of other fibrosis prediction tools: LSM-VCTE alone, and common, easily available scores (FIB-4 or APRI).
Methods
Single-center, retrospective study, on consecutive patients with baseline laboratory tests, liver biopsy, and reliable LSM-VCTE measurements. The discrimination between tests was evaluated by analyzing the AUROCs. Dual cut-off approaches were applied to rule-out and rule-in ≥F3, F4 and fibrotic NASH. We tested previously reported cut-off values and provided our best thresholds to achieve Se ≥85%, Se ≥90%, and Sp ≥90%, Sp ≥95%.
Results
Among 246 patients, 113 (45.9%) were women, and 75 (30.5%) presented diabetes. Agile 3+ and Agile 4 demonstrated excellent performance in identifying ≥F3 and F4, achieving AUROCs of 0.909 and 0.968, while the FAST score yielded acceptable results in distinguishing fibrotic NASH. When compared to FIB-4 and LSM-VCTE, both Agile 3+ and Agile 4 performed better than FIB-4 and had a similar performance to LSM-VCTE, but with higher diagnostic accuracy, hence reducing the grey zone.
Conclusion
Agile 3+ and Agile 4 are reliable, non-invasive tests for identifying advanced fibrosis or cirrhosis in MASLD patients, while FAST score demonstrates moderate performance in identifying fibrotic NASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Cluj, Romania.
- Regional Institute of Gastroenterology and Hepatology "Octavian Fodor", Cluj-Napoca, Cluj, Romania.
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
ORCID-Profile: Cristian Tefas, Monica Lupsor-Platon, Horia Stefanescu
Förderung
- UEFISCDI, the Romanian Executive Agency for Higher Education, Research, Development, and Innovation Funding
- Ministry of Scientific and Technological Development, Higher Education and Information Society
- University of Medicine and Pharmacy “Iuliu Hațieganu” Cluj-Napoca
Zitieren
APA
Taru, M. G., Tefas, C., Neamti, L., Minciuna, I., Taru, V., Maniu, A., Rusu, I., Petrushev, B., Procopciuc, L. M., Leucuta, D. C., Procopet, B., Ferri, S., Lupsor-Platon, M., & Stefanescu, H. (2024). FAST and Agile–the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin. PLOS ONE, 19(5), e0303971. https://doi.org/10.1371/journal.pone.0303971
Vancouver
Taru MG, Tefas C, Neamti L, Minciuna I, Taru V, Maniu A, et al. FAST and Agile–the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin. PLOS ONE. 2024;19(5):e0303971. doi:10.1371/journal.pone.0303971
BibTeX
@article{Taru2024,
author = {Taru, Madalina-Gabriela and Tefas, Cristian and Neamti, Lidia and Minciuna, Iulia and Taru, Vlad and Maniu, Anca and Rusu, Ioana and Petrushev, Bobe and Procopciuc, Lucia Maria and Leucuta, Dan Corneliu and Procopet, Bogdan and Ferri, Silvia and Lupsor-Platon, Monica and Stefanescu, Horia},
title = {FAST and Agile–the MASLD drift: Validation of Agile 3+, Agile 4 and FAST scores in 246 biopsy-proven NAFLD patients meeting MASLD criteria of prevalent caucasian origin},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {5},
pages = {e0303971},
doi = {10.1371/journal.pone.0303971}
}
EUVIMED